Eli Lilly and (NYSE:LLY)‘s stock had its “sell” rating restated by research analysts at BMO Capital Markets in a research note issued on Tuesday. They currently have a $73.00 price objective on the stock. BMO Capital Markets’ price objective indicates a potential downside of 15.77% from the stock’s current price.
Several other research analysts have also weighed in on the company. Morgan Stanley lifted their price objective on Eli Lilly and from $86.00 to $90.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 21st. Zacks Investment Research lowered Eli Lilly and from a “buy” rating to a “hold” rating in a research report on Monday, October 30th. Berenberg Bank reissued a “buy” rating and issued a $98.00 price objective on shares of Eli Lilly and in a research report on Thursday, October 26th. Leerink Swann lifted their price objective on Eli Lilly and from $92.00 to $93.00 and gave the stock a “market perform” rating in a research report on Monday, October 23rd. Finally, Piper Jaffray Companies reissued a “buy” rating and issued a $105.00 price objective on shares of Eli Lilly and in a research report on Friday, October 13th. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and nine have given a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $90.25.
Eli Lilly and (LLY) traded up $0.22 during mid-day trading on Tuesday, hitting $86.67. The stock had a trading volume of 3,336,800 shares, compared to its average volume of 3,672,243. Eli Lilly and has a 1 year low of $67.42 and a 1 year high of $89.09. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.03 and a current ratio of 1.38. The company has a market cap of $95,189.66, a price-to-earnings ratio of 21.14, a PEG ratio of 1.90 and a beta of 0.35.
Eli Lilly and (NYSE:LLY) last posted its quarterly earnings data on Tuesday, October 24th. The company reported $1.05 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.03 by $0.02. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The firm had revenue of $5.66 billion during the quarter, compared to analyst estimates of $5.52 billion. During the same period last year, the company posted $0.88 EPS. The business’s quarterly revenue was up 9.0% on a year-over-year basis. equities analysts forecast that Eli Lilly and will post 4.21 earnings per share for the current year.
In related news, SVP Susan Mahony sold 36,585 shares of the business’s stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $86.18, for a total value of $3,152,895.30. Following the completion of the sale, the senior vice president now directly owns 54,885 shares of the company’s stock, valued at approximately $4,729,989.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Lilly Endowment Inc sold 190,000 shares of the business’s stock in a transaction dated Friday, September 15th. The shares were sold at an average price of $82.53, for a total value of $15,680,700.00. Following the completion of the sale, the insider now directly owns 123,682,287 shares of the company’s stock, valued at $10,207,499,146.11. The disclosure for this sale can be found here. Insiders sold a total of 628,588 shares of company stock valued at $53,399,536 over the last ninety days. 0.20% of the stock is currently owned by corporate insiders.
A number of institutional investors and hedge funds have recently modified their holdings of the business. Steward Partners Investment Advisory LLC bought a new stake in Eli Lilly and during the 3rd quarter worth approximately $916,000. Public Employees Retirement System of Ohio increased its holdings in Eli Lilly and by 0.4% during the 3rd quarter. Public Employees Retirement System of Ohio now owns 684,533 shares of the company’s stock worth $58,555,000 after purchasing an additional 2,452 shares in the last quarter. Garde Capital Inc. bought a new stake in Eli Lilly and during the 3rd quarter worth approximately $202,000. Archford Capital Strategies LLC increased its holdings in Eli Lilly and by 26.2% during the 3rd quarter. Archford Capital Strategies LLC now owns 8,076 shares of the company’s stock worth $690,000 after purchasing an additional 1,676 shares in the last quarter. Finally, Salem Investment Counselors Inc. increased its holdings in Eli Lilly and by 7.5% during the 3rd quarter. Salem Investment Counselors Inc. now owns 48,460 shares of the company’s stock worth $4,173,000 after purchasing an additional 3,400 shares in the last quarter. 76.42% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: This piece of content was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2017/12/12/eli-lilly-and-lly-earns-sell-rating-from-bmo-capital-markets.html.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.